Jama Pitman Sells 1,298 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Stock

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPHGet Rating) insider Jama Pitman sold 1,298 shares of the business’s stock in a transaction that occurred on Thursday, June 16th. The shares were sold at an average price of $10.75, for a total value of $13,953.50. Following the completion of the transaction, the insider now directly owns 36,661 shares in the company, valued at $394,105.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

NASDAQ DCPH opened at $13.13 on Thursday. The business has a 50 day moving average price of $10.85 and a 200-day moving average price of $9.55. Deciphera Pharmaceuticals, Inc. has a 52 week low of $6.51 and a 52 week high of $13.19.

Deciphera Pharmaceuticals (NASDAQ:DCPHGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.03. Deciphera Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 279.96%. The business had revenue of $29.22 million during the quarter, compared to the consensus estimate of $27.17 million. During the same quarter in the prior year, the company posted ($1.06) earnings per share. Deciphera Pharmaceuticals’s revenue was up 16.2% compared to the same quarter last year. On average, equities analysts anticipate that Deciphera Pharmaceuticals, Inc. will post -2.62 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA grew its holdings in Deciphera Pharmaceuticals by 17.0% during the first quarter. BNP Paribas Arbitrage SA now owns 23,557 shares of the company’s stock worth $218,000 after buying an additional 3,417 shares in the last quarter. Ensign Peak Advisors Inc boosted its position in Deciphera Pharmaceuticals by 4.4% in the first quarter. Ensign Peak Advisors Inc now owns 39,850 shares of the company’s stock worth $369,000 after purchasing an additional 1,670 shares during the last quarter. PDT Partners LLC purchased a new position in Deciphera Pharmaceuticals in the first quarter worth $2,061,000. Pinz Capital Management LP purchased a new position in Deciphera Pharmaceuticals in the first quarter worth $1,537,000. Finally, Invesco Ltd. boosted its position in Deciphera Pharmaceuticals by 134.6% in the first quarter. Invesco Ltd. now owns 61,284 shares of the company’s stock worth $569,000 after purchasing an additional 35,157 shares during the last quarter. Institutional investors and hedge funds own 87.97% of the company’s stock.

Separately, Barclays downgraded Deciphera Pharmaceuticals from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $11.00 to $6.00 in a report on Monday, February 28th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $24.75.

About Deciphera Pharmaceuticals (Get Rating)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.

Read More

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.